Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New approach to targeted cancer therapy


Despite many advances in medicine, cancer remains the most common cause of death in Germany and the Western World. The further development of diagnostic tests and treatment is not only essential for individual patients, but also represents an enormous challenge to our public health care system. Scientists in Cologne led by Prof. Christian Reinhardt have identified a new approach to targeted cancer therapy.

Through the molecular characterization of tumor cells, Prof. Christian Reinhardt and his team of scientists at the University of Cologne and CECAD have developed a new approach to treating cancer.

“These new findings offer a novel molecular approach to treating genetically-defined cancers more effectively in the future,” says Prof. Reinhardt, lead scientist of this new study, of the recent research success. An international team of scientists from Germany, Denmark and England was involved in the study, which has been published today in the high impact journal Cell.

In the Department of Internal Medicine I at the University of Cologne, Prof. Reinhardt leads a research group that is substantially sponsored by the German Research Foundation (DFG), teh German Cancer Aid, and the Volkswagen Foundation.

With the aid of a new screening procedure, the research team has tested the efficacy of various compounds and, in particular, of novel compound combinations. Analytical results showed that tumor cells and cancers with a mutation in the KRAS gene depend on two distinct enzymes (Chk1 and MK2). The KRAS gene is one of the most commonly mutated genes appearing in human cancer cells.

Mutated KRAS is found in almost all pancreatic cancers, and about one-third of lung and colorectal cancers. Detailed analyses showed that KRAS mutations lead to massively increased cell growth. But the very rapid proliferation of cancer cells causes problems: DNA duplication that has to take place prior to every cell division is much more difficult for cancer cells under conditions of accelerated growth.

The latest data from the Cologne scientists show that KRAS-mutated cancer cells rely on MK2 and Chk1 enzyme function for error-free duplication of their DNA. This dependence on MK2 and Chk1 distinguishes KRAS-mutant cancer cells from healthy tissue, which is capable of duplicating DNA without these particular enzymatic functions.

And the new therapeutic approach is based on this very difference between cancer cells and normal tissue. The research team has shown that tumor cells and cancers with KRAS mutations respond very well to combination therapy with Chk1 and MK2 inhibitors. Normal tissue, on the other hand, tolerates the combination therapy well and has very little in the way of adverse reactions.

Taking a closer look at these enzymes, Chk1 and MK2 are protein kinases. In the last 10 years, this particular enzyme group has increasingly come to the attention of the big pharmaceutical companies. Enzymes can potentially be inhibited and therefore provide options for developing new therapeutic agents.

The combined pharmacological inhibition of Chk1 and MK2 is a therapeutic strategy that could be used specifically for treating KRAS-mutated cancers. “Chk1/MK2 inhibition works specifically in KRAS-mutant cancer cells. Normal tissue isn’t really affected, because healthy cells don’t contain KRAS genes that have undergone mutation,” explains Dr. Felix Dietlein, lead author of the publication, when describing the therapeutic concept.

Prof. Michael Hallek, Head of the Department of Internal Medicine I at the University of Cologne, finds the new therapeutic approach very promising. “MK2 is a protein kinase that has been investigated in depth for some time, as its function seems to have a role in the development of rheumatoid disease.

The protein kinase Chk1 has also been closely scrutinized in recent years, and the first clinical trials of various Chk1 inhibitors are now underway. These fascinating findings may provide treating physicians with an effective new tool for treating KRAS-mutant cancers in the near future,” he confirms.

Even though they have been the subject of research and development as medicinal products for some time, none of the MK2 inhibitors has yet obtained regulatory approval. Work on this project was generously sponsored by the German Research Foundation (DFG), German Cancer Aid, and the Volkswagen Foundation.

For CECAD and the University Hospital Cologne, the development of this new therapeutic approach represents a significant and promising opportunity: additional treatment options for the fight against cancer in the near future – an important aspect of aging research at the Cluster of Excellence.

Prof. Christian Reinhardt
CECAD, University of Cologne
Department of Internal Medicine I
Cologne University Hospital
Phone +49 221 478-96701

Astrid Bergmeister MBA
Head of CECAD PR & Marketing
University of Cologne
Phone + 49 (0) 221-478 84043

Weitere Informationen:

Astrid Bergmeister | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Signaling Pathways to the Nucleus
19.03.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht In monogamous species, a compatible partner is more important than an ornamented one
19.03.2018 | Max-Planck-Institut für Ornithologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

A new kind of quantum bits in two dimensions

19.03.2018 | Physics and Astronomy

Scientists have a new way to gauge the growth of nanowires

19.03.2018 | Materials Sciences

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Science & Research
Overview of more VideoLinks >>>